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tive protein15, is increased in chronic haemodialysis pa-
tients16,18, is increased in type 2 diabetic patients with 
microvascular complications19 and is increased ih heart 
failure after acute myocardial infarction20. This has led 
to interesting debate about potential role of OPG as a vas-
cular disease biomarker. Exact mechanism by which OPG 
affects cardiovascular pathology is still unclear. The need 
for complete picture is directed to valuable researches, 
that show OPG is not only marker but mediator in vascu-
lar pathology that modulates osteogenic, infl ammatory 
and apoptotic response7,8. Integrating results above shown 
of recent experimental research, in animal models, and 
human studies till year 2010 this review demonstrates 
role of OPG in vascular pathology.
Since its initially discovered in 1997 as a key regulator 
in bone turnover1, osteoprotegerin (OPG) has became sub-
ject of intense research in its role as a common mediator 
of bone metabolism and vascular calcifi cation and vascu-
lar diseases2–6. Extracelular matrix calcifi cation is normal 
physiological process, necessary for proper development of 
tissues like bone, teeth and cartilage. However when it 
occurs in tissues that normally do not mineralize, calcifi -
cation can lead to serious conceqences. Researches in vi-
tro, and in animal models show that OPG inhibits vascu-
lar calcifi cation7–12. Paradoxically, clinical researches have 
shown that OPG serum levels is increased in patients with 
progressive cardiovascular disease13, correlates with pres-
ence and severity of coronary artery disease (CAD)14, is 
associated with left ventricular hypertrophy and C-reac-
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A B S T R A C T
Osteoprotegerin (OPG) is a key regulator in bone metabolism, that also has effect in vascular system. Studies suggest 
that osteoprotegerin is a critical arterial calcifi cation inhibitor, and is released by endothelial cells as a protective mech-
anism for their survival in certain pathological conditions, such as diabetes mellitus, chronic kidney disease, and other 
metabolic disorders. That has been shown in studies in vitro and in animal models. The discovery that OPG defi cient 
mice (OPG -/- mice) develop severe osteoporosis and arterial calcifi cation, has led to conclusion that osteoprotegerin might 
be mulecule linking vascular and bone system. Paradoxically however, clinical trials have shown recently that OPG serum 
levels is increased in coronary artery disease and correlates with its severity, ischemic cardial decompensation, and future 
cardiovascular events. Therefore it is possible that osteoprotegerin could have a new function as a potential biomarker in 
early identifi cation and monitoring patients with cardiovascular disease. Amongst that osteoprotegerin is in association 
with well known atherosclerosis risc factors: undoubtedly it is proven its relationship with age, smoking and diabetes 
mellitus. There is evidence regarding presence of hyperlipoproteinemia and increased serum levels of osteoprotegerin. Also 
the researches have been directed in genetic level, linking certain single nucleotid genetic polymorphisms of osteoprote-
gerin and vascular calcifi cation appearance. This review emphasises multifactorial role of OPG, presenting numerous 
clinical and experimental stydies regarding its role in vascular pathology, suggesting a novel biomarker in cardiovascu-
lar diseases, showing latest conclusions about this interesting topic that needs to be further explored.
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OPG/RANK/RANKL/TRIAL System
OPG known as a factor that inhibits osteoclastogenesis 
(OCIF) is a glycoprotein, member of tumor necrosis factor 
superfamily (TNF). It is a basic glycoprotein comparising 
401 amino acid residues arranged into 7 structural do-
mains. It is found as either a 60 kDa monomer or 120 kDa 
dimer linked by disulfi de bonds1. It has a pleiotropic effect 
in bone metabolism, endocrine and immunological system. 
Osteoprotegerin (OPG) and receptor activator for nuclear 
factor kappaB ligand (RANKL) are cytokines tradition-
ally associated with bone turnover. RANKL activates os-
teoclasts and bone resorption, while OPG acts as a decoy 
receptor for RANKL, inhibiting bone resorption. The net 
of these cytocines regulates differentiation and activation 
of osteoclasts and holds balance between bone osteoclasts 
and osteoblasts4. RANKL is expressed at osteoblasts, stro-
mal cells and T cells, binding RANK at the surface of 
osteoclasts, monocites and dendritic cells5,21. OPG, a solu-
ble glycoprotein is widely expressed on most human tis-
sues, including bone (osteoblasts) and vasculature (endotel 
and vascular smooth muscle cells (VSMV)). Acting as a 
soluble decoy receptor competing for RANKL, OPG pre-
vents RANK-RANKL interaction, thus inhibiting osteo-
clastic differentiation and bone resorption4,5,8. As a mem-
ber of tumor necrosis factor superfamily (TNF) OPG 
modulates infl ammatory response and has antiapoptotic 
effect. OPG as well neutralizes pro-apoptotic activity in-
duced by tumor necrosis factor-related apoptosis-inducing 
ligand (TRIAL), that is expressed at VSMC and T cells22,23.
Vascular Calcifi cation
Vascular calcifi cation often occures in procesess of ag-
ing, progression of atherosclerosis, and in specifi c meta-
bolic disorders, such as diabetes mellitus, and end stage 
renal disease, leading to severe clinical consequences. 
Such calcifi cation can appear in various places such as 
heart valves, arterial intima and media, capilares, form-
ing localised or diffuse calcifi cation, causing active im-
munological response and mineral homeostasis disbal-
ance. Just recently discovered RANKL/RANK/OPG 
system, are domain of vascular biology widely exproled as 
factors essential in regulation of vascular calcifi cation, 
immune response, and bone turnover8. From a histoana-
tomical perspective, vascular calcifi cation may be classi-
fi ed based on its location, association with plaque, and 
mode of formation2. Whereas a minor form of widespread 
nonspecifi c organ and soft tissue calcifi cation derives from 
abnormal calcium/phosphate products, more common 
types of vascular calcifi cation may occur by actively regu-
lated processes in the absence of raised calcium/phosphate 
levels. Morphologically, these types of calcifi cation are dis-
tinguishable by whether calcifi cation primarily takes 
place in cardiac valves, in arterial intimal layers in as-
sociation with macrophages and lipid and vascular smooth 
muscle cells (VSMCs) as in atherosclerosis, or in arterial 
media layers because of elastin fi ber mineralization as in 
end-stage renal disease or diabetes mellitus. Like most 
biological processes, vascular calcifi cation is actively regu-
lated by the networks that involve positive and negative 
regulators, temporal expression or activation of modula-
tors, and multiple amplifi cation or suppressive feedback 
loops that orchestrate cell recruitment, differentiation, 
function, survival, and interactions with other cells or ma-
trix molecules2,3,24. Mounting evidence suggests that 
RANK, RANKL, and OPG may participate in multiple 
aspects of these processes governing vascular calcifi ca-
tion.
Traditionally it is assumed that vascular calcifi cation 
is passive process of calcium relocalisation from bone tis-
sue to vasculature. However complex interactions between 
inhibitors and promotors of vascular calcifi cation are ob-
served. In normal vasculature, different group of regula-
tory factors such as an extracellular pyrophosphate (PPi), 
muscle glycogen phosphorylase (MGP), fetuin, osteopontin 
and OPG inhibiting process of calcifi cation in the vascu-
lature25. In atherosclerosis, as in calcifi c aortic valve ste-
nosis infl ammatory markers inculding activated mac-
rofages and T cells initialize active bone tissue formation. 
Increased expression of RANKL and decreased expression 
of OPG are found at the cells of localized calcifi c areas26. 
As opposed to calcifi cation of arthery media, OPG expres-
sion is increased in calcifi c areas, while RANKL expres-
sion is decreased27. In vasculature with endothelial dys-
function (diabetes mellitus, end-stage renal disease), 
earlier mentioned inhibitory factors (for vascular calcifi ca-
tion) may become weak, and therefore make vasculature 
submissive for actions of vascular calcifi cation promotors 
such as toxic effect of hyperglicaemia, endothelin-1, alka-
line phosphatase (ALP), bone morphogenetic proteins 2 
and 4 (BMP-2, BMP-4), transforming growth factor-beta 
(TGF-beta), RANKL25. Macrovascular complications such 
as cardiovascular diseases and peripheral artery diseases 
are leading cause of increased mortality and morbidity, 
especially in diabetes mellitus patients. Macrovascular 
impairment etiopathogenesis in diabetes mellitus is mul-
tifactorial, and differens in diabetes typ 1 or 2. Endothe-
lial cell dysfunction is early vascular alteration in diabetes 
mellitus typ 2, and is associated with poor regulation of 
glycemic status. Chronic hyperglycemia may cause dam-
age of vascular milleu leading in long tearm to early apop-
tosis of endothelial cells. Appoptotic cells exsistance in 
valcular lumen may trriger reaction cascade between pro-
motors and inhibitors of artherial calcifi cation25.
Medial artery calcifi cation is a typical feature in dia-
betes mellitus, and an important predictor of cardiovas-
cular disaeses8,25. It occurs mainly independently of ath-
erosclerosis. Medial artey calcifi cation occures in normal 
calcium and phosphate serum levels, which is opposite to 
vascular calciphylaxis, a form that occures in high serum 
calcium-phosphate product levels, and make widespread 
tissue deposition into elastic fi bers3,25. Intimal calcifi cation 
(another form of calcifi cation) is commonly associated with 
atherosclerosis, characterized by lipid accumulation, in-
fl ammation, fi brosis and development of focal plaques8.
Medial artery calcifi cation in diabetes mellitus is as-
sociated with OPG, that has been detected in calcifi ed 
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regions of athero sclerosis and of medial artery calcifi ca-
tion, associated with enhanced apoptosis, suggesting a 
signifi cant role for the regulators of bone metabolism in 
the pathogenesis of medial artery calcifi cation in patients 
with diabetes27. Therefore, OPG is an important modula-
tor of bone metabolism, and manifests its effect not only 
in bone but in arteries28. Considering all this it seems that 
osteoprotegerin is a key inhibitor of artery calcifi cation, 
and is released by endothelial cells as a protective mecha-
nism in certain conditions (diabetes mellitus, end stage 
renal disease)12. It is therefore a potential marker for ear-
ly identifi cation and monitoring of impaired mineral me-
tabolism and vasculopathy in diabetes mellitus pa-
tients27,29.
Osteoprotegerin and Atherosclerosis Risc 
Factors
Present studies identifi ed high OPG serum levels as 
an independed risc factor for progressive atherosclerosis 
and incidence of cardiovascular diseases in general popu-
lation7,13. These fi ndings might be relevant in routine 
asessment of vascular risc. However it can not be comple-
telly roule out the possibility that high OPG serum levels 
are barely an epiphenomena of infl ammatory process in 
atherosclerotic tissue. Nevertheless number of experimen-
tal studies confi rm active role of OPG in vascular pathol-
ogy3–6,8,10,11. It is yet to explore whether OPG acts as a 
causative risc factor or it has a contraregulatory protective 
mechanism in atherosclerosis.
It is found arguably that OPG strongly correlates with 
age30,31. In patients stratifi cated by gender and age OPG 
was higher in patients with diabetes mellitus29,30. It is as-
sociated with smoking30.
The prevalence and severity of atherosclerosis on ca-
rotid artery (caritid artery disease) signifi cantly increased 
with higher OPG levels. After adjustment for age and gen-
der, correlation decresed but was still signifi cant30.
Age, female gender, black rase, smoking, personal and 
family anamnesis of coronary artery disease, diabettes 
mellitus, hyperlipoproteinemia, signifi cantly correlates 
with higher OPG surum levels30.
In the study based on 3,386 subjects aged 30–65 years, 
Abedin et al. found high OPG levels to be independently 
associated to coronary artery calcifi cation and aortic 
plaque, and to correlate to its severity, after adjustment 
for age, gender, smoking anamnesis, diabetes mellitus, 
hyperlipoproteinemia, and family anamnesis of early 
coronary artery disease onset30. These fi ndings suggest 
its role as a novel atherosclerosis biomarker.
In accordance with previous and present researches, 
Szulc et al.32 demonstrated that serum OPG levels positive 
correlate to age in the study including 252 healthy men 
age 19–85, also Fahrleitner-Pammer et al.33 in a study 
including 177 healthy women showed positive correlation 
to age, but not to bone mass or bone turnover markers.
Protective Role of OPG on Vascular 
Calcifi cation: Possible Underlying Mechanism
OPG and RANKL have an important role in osteo-
genic modulation of vasculature. OPG is produced by 
various tissues, mainly endothelial cells-vascular smooth 
muscle cells (VSMCs) with high levels especially in aortic 
and renal arteries34. As opposed to OPG, RANKL is not 
usually detected in normal vasculature5,34. OPG has indi-
rect anti-apoptotic and protective effect on endothelial 
cells, acting as a decoy receptor for tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL)12,22.
In bone milieu, RANKL has a function of central os-
teoclasts maturation factor, promoting osteoclastic activ-
ity and bone resorption, while OPG oppose RANKL ac-
tion34. RANKL promotes, and OPG protects against 
vascular calcifi cation27,34.
High OPG levels seen in endothelial dysfunction, may 
be barely compensatory mechanism by endothelial cells to 
protect against TRAIL apoptosis. In relation to that, high 
OPG levels may be survival factor for endothelial cells12,35. 
In contex of endothelial cell dysfunction these vascular 
cells may overexpress OPG12. This process may continue 
to calcifi cation process, in fact, OPG level may continue 
increasing as calcifi cation progresses27. According to that, 
vascular calcifi cation inhibition processes are tightly reg-
ulated by protective pathways as a response to metabolic 
and infl ammatory stimulation.
High OPG levels correlate to high infl ammatory mark-
ers (CRP, interleukine 6 (IL-6), and fi brinogene), as well 
with HbA1c level and insulin resistance35. It seems that 
OPG expression on vascular cells has signifi cant protec-
tive effect against vascular calcifi cation, thus against cal-
cifi cation of artery media28. The presence of hyperglycae-
mia, oxidative stress, activated cytocine net and other 
effective stimulus can eventually let vascular calcifi cation 
promotors prevailed this protective mechanism thus ac-
celerate calcifi cation process29. Preventing calcifi cation 
progression, osteoblast-lile cells and vascular cells near 
matrix can further increase OPG production. These pro-
cesses of inhibition and promotion may be progressive and 
continuing till forming bone like tissue in the vasculature 
wall28,29.
Animal Model Overview
In the mouse model, OPG defi cient mice (OPG -/- mice) 
resulted in severe osteoporosis, but also unexpected vas-
cular calcifi cation fenotipe10. There ‘s endogenous OPG 
expression on aorta and renal arteries, and exactly these 
arteries develope calcifi cation lesions in OPG -/- mice10.
Studies have shown these calcifi cation include bone 
matrix such as hydroxiapatite, bone proteins, as well as 
growth factors, and adhesive molecules36.
This dual phenomena of osteoporotic bone loss and ar-
terial calcifi cation is proven in the OPG -/- mice model. 
These arteries (aorta and renal arteries) are precisely the 
places with the most common calcifi cation development in 
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humans with severe atherosclerosis. Although artery cal-
cifi cation in OPG -/- mice develope in absence of lipid de-
position and other vascular lesion normally presented in 
patients with atherosclerosis. In addition, the difference 
is in the fact that, artery calcifi cation in atherosclerosis is 
a late event, whereas artery calcifi cation in OPG -/- mice 
is an early event10.
Mouse rescue experiments show that expression of 
OPG as a transgene on an OPG null background prevent-
ed the onset of arterial calcifi cation, indicating that sys-
temic OPG plays a protective role in major arteries. How-
ever, injection of a high dose of recombinant OPG into 
adult OPG−/− mice did not affect the incidence of arterial 
calcifi cation, indicating that OPG cannot reverse the cal-
cifi cation process. It is not clear from these data whether 
the size of calcifi ed lesions stopped increasing in the OPG-
injected group. Delivery of OPG to younger animals, or 
treatment for >4 week, will be necessary to determine 
whether OPG can stop further progression of vascular 
calcifi cation9.
Calcifi cated vascular lesion contain various bone ma-
trix proteins such as colagen typ I, osteocalcin and bone 
morphogenic protein 237–39.
In another animal model study, male OPG (–/–), OPG 
(+/–), and OPG (+/+) mice were fed a high phosphate diet 
from 6 to 10 weeks after birth, and then 1α,25-
dihydroxyvitamin D3 (calcitriol) was injected for 3 days. 
They found that severe calcifi cation developed in the me-
dia of the aorta in OPG (–/–) mice. Under electron micros-
copy, calcium deposits were observed in the cytoplasm and 
extracellular matrix of vascular smooth muscle cells 
(VSMCs). Neither apoptosis of VSMCs nor infi ltration of 
macrophages was observed. ALP activity of aortic tissue 
correlated with the calcifi ed lesion area. Mouse aorta and 
bone extracts revealed an identical pattern by ALP elec-
trophoresis40. That demonstrated that OPG had anticalci-
fi cation activity in the aorta, probably through the down-
regulation of ALP activity, since in this study authors 
clearly indicated that ALP activity in the aorta is in-
creased and may contribute to aortic calcifi cation.
Vascular Calcifi cation and OPG Serum 
Concentration in Humans
As already previously shown high serum OPG levels 
correlate to age, diabetes mellitus, hypertension, high car-
diovascular mortality, presence and severity of coronary 
artery disease, end stage renal disease4,5,17–19,41. Serum 
OPG levels decreasing in patients on immunosuppressive 
or glucocorticoide therapy42–44.
Intimal vascular calcifi cation is objective marker of 
atherosclerosis, and its severity is independent risk factor 
for cardiovascular disease development45. Coronary or 
aortic calcifi cation assessment demand CT scanning, 
analyses and evaluation data, to provide their accuracy46. 
Potential blood marker used for vascular calcifi cation 
quantifi cation, could be used as a coronary artery disease 
risc factor, and its advantage would be accessibility, non-
exposure to iradiation, noninvasive testing, and lower 
price comparing to invasive examination.
According to the fi nding that serum OPG is increased 
in conditions that are supported by atherosclerosis4,5,17–19, 
there is a possibility of using serum osteoprotegerin in 
predicting vascular calcifi cation and cardiovascular risc, 
thus serve as a marker for vascular calcifi cation. Further 
studies are needed to evaluate its exact clinical usage.
Human Studies on OPG and Vascular 
Calcifi cation
In the study on 102 subjects both men and women un-
dergoing haemodialysis, was found that serum OPG levels 
were higher in haemodialysis patients and increased with 
the grade of aortic calcifi cation. In this study multiple re-
gression analyses indicated that serum OPG levels were 
independently associated with the severity of aortic calci-
fi cation16. However, the mechanism whereby serum OPG 
was related to the progression of vascular calcifi cation in 
dialysis patients is unknown.
The abdominal aorta was studied by non-contrast CT 
scanning in consecutive sequential 8 mm slices and the 
aortic calcifi cation index (ACI) was estimated as the pro-
portion of aortic circumference covered by calcifi cation. By 
this method, arteriosclerosis was quantifi ed morphometri-
cally in the cross section with the most extensive aorto-
sclerosis. The arithmetic mean values of three measure-
ments were calculated and used for analysis. The patients 
were divided into four groups according to their ACI: 
group I (ACI 0–10%), group II (ACI 11–30%), group III 
(ACI 31–50%) and group IV (ACI 51–100%)16. Multiple 
regression analyses were performed to adjust for the roles 
of different pathogenic factors on vascular calcifi cation 
(serum levels of albumin, total cholesterol, triglyceride, 
diastolic and systolic blood pressure or the calcium x phos-
phate (Ca x P) product). Serum OPG and CRP levels were 
independently associated with the extent of vascular cal-
cifi cation16. These fi ndings suggest not only the posibillity 
that serum OPG could serve as a biomarker for vascular 
calcifi cation, but also suggesting that OPG may be in-
volved in the development of vascular calcifi cation in hae-
modialysis patients.
As it is established in the reaserch on 515 patients on-
dergoing haemodialysis vascular calcifi cation severity 
impaire the outcome in these patients, and is a predictor 
for cardiovascular mortality47. Considering this, the sig-
nifi cance of serum osteoprotegerin in these patients might 
be great for determination of their prognosis among other 
known risc factors.
Other research with peripheral artery disease patients 
shown connection between serum OPG levels and infra-
renal and abdominal aortic calcifi cation severity. The in-
frarenal arteries and abdominal aorta were studied by 
non-contrast CT scanning for calcifi cation assessment48. 
These connection provides potential value of serum OPG 
in predicting infrarenal and aortic calcifi cation in these 
patients, proving value of serum OPG in another popula-
tion of patients.
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Osteoprotegerin and Coronary Artery 
Disease
The protective role of OPG, in animal models, against 
vascular calcifi cation has not been replicated in human 
trials; moreover, increased OPG levels have been consis-
tently associated with the incidence and prevalence of 
coronary artery disease. There seems to be some dichoto-
my in the role of OPG, RANKL, and tumor necrosis factor-
related apoptosis-inducing ligand in atherosclerosis and 
plaque stability49. In previous studies has been shown that 
serum OPG levels signifi cantly increased with coronary 
artery disease severity. Serum OPG levels increased in 
the presence of one, two or three wessel disease13–15. Over-
all, these researches show that serum OPG levels increase 
in conditions with vascular calcifi cation, and is connected 
with acutisation of coronary artery disease, due to plaque 
instability49.
In the study regarding association of OPG with the 
presence and severity of CAD, serum OPG levels was mea-
sured in 201 patients to whom was performed coronarog-
raphy, because of the chest pain. The severity of CAD was 
assessed in coronarography and was classifi ed by the 
number of stenotic coronary arteries. Serum OPG levels 
were measured by ELISA, and were signifi cantly higher 
in patients with CAD, then those without, and signifi cance 
increased by increasing severity of CAD14. These insights 
show that altered serum OPG levels may refl ect the status 
and severity of CAD, thus the status of vascular calcifi ca-
tion. These fi ndings are based on the opinion that OPG 
play an important role in pathophisiology of atherosclero-
sis7. The exact mechanism by which serum OPG is altered 
in these patients is still unclear, but there is a posibility 
that increased serum OPG present insuffi cient compensa-
tory mechanism to prevent initiated vascular calcifi cation 
cascade.
The study regarding relationship between serum OPG 
levels with CAD severity, left ventricular hypertrophy and 
C-reactive protein, shwn as well that serum OPG levels 
were higher in patients with three wessel disease compar-
ing to those with -two, -one or no wessel disease. The same 
was shown for the CRP. Correlation was positive even af-
ter ajustment for age.
Age and LV mass index also positive correlated to se-
rum OPG levels, but this signifi cance was lost after ajust-
ment for age. Two-dimensional echocardiography and M-
mode echocardiography was used to measure the wall 
thickness and the internal diameter, and both were mea-
sured at end-diastole. There was no signifi cant gender 
difference in OPG levels15. Interestingly, in this study the 
association of OPG with infl ammatory markers is shown. 
OPG functions as a soluble decoy receptor for receptor ac-
tivator of nuclear factor-κB (RANK) ligand (RANKL or 
OPG ligand). RANKL is produced by osteoblastic lineage 
cells and activated T lymphocytes and stimulates its recep-
tor, RANK, which is located on osteoclasts and dendritic 
cells21. OPG, RANKL, and RANK act as key regulators of 
bone metabolism and the immune system. Because vascu-
lar diseases are promoted by immune-mediated mecha-
nisms, OPG may be involved in the progression of athero-
sclerosis7. OPG is also a receptor for the cytotoxic ligand 
TNF-related apoptosis inducing ligand (TRAIL), a potent 
activator of apoptosis. One possibility is that OPG infl u-
ences vascular disease by inhibiting TRAIL-induced apop-
tosis of vascular cells22,23.
Although the mechanism for the vascular effects of 
OPG is unknown, emerging evidence indicates OPG may 
act as a protective factor for vascular diseases. One hy-
pothesis is that increased serum OPG levels may be a 
compensatory self-defensive response to the progression of 
atherosclerosis14.
Osteoprotegerin and Aortic Valve Stenosis
Over the past 10 to 15 years, calcifi c aortic valve dis-
ease, which includes aortic sclerosis and aortic stenosis, 
has become recognized as an active process. Calcifi cation 
and fi brosis are the main feature of aortic valve stenosis. 
Calcifi cation contributes to the rigidity of the valve, there-
by increases LV outfl ow obstruction. Numerous studies 
prove that calcifi c aortic valve stenosis is an active, rather 
than passive process, as was thought earlier50–52. Valvular 
calcifi cated deposits contain calcium and phosphates in 
the forme of hydroxiapatite, calcium-phosphate mineral, 
that is present in calcifi ed arterial tissue and in bone for-
mation37,50,51. Proteins involved in tissue calcifi cation reg-
ulation detected in calcifi c valvular tissue, include bone 
morphognetetic proteins (BMPs) 2 and 426,52, RANKL52, 
and osteopontin53–55. RANK is expressed on normal valve 
cuspes, but downregulated on aortic valve lesions26.
In aortic valve lesions, calcifi c noduli appears to de-
velop their formation fi rst in lesions of lipid deposition, 
especially those with oxidized lipids56. Aortic valve lesions 
contain as well tenascin C, an extracelular matrix gly-
coprotein in developing bone57. Recently a subgroup of 
valvular fi broblasts have been discovered, that express 
osteoblasts markers and forming hydroxiapatite sponta-
neously-containing calcifi ed noduli in vitro26,51. In re-
sponse to oxidized cholesterol51, transforming growth fac-
tor beta1(TGF beta 1)51, BMP 251 and RANKL26 increase 
their expression of osteoblast markers, thereby increasing 
the extent of calcifi ed noduli formation. In addition, tenas-
cin C increasing expression of matrix metaloproteinase 2 
(MMP 2) in those cells57.
As well, it was shown that hyperphosphatemia induces 
calcifi ed vesicular formation in the miofi broblasts, thus 
suggesting possible mechanism linking chronic renal dis-
ease and valvular calcifi cation52,58,59.
Recent study shown that by immunohistochemistry 
using human aortic valves, RANKL was not expressed at 
relevant levels in controls but detectable in aortic valve 
stenosis60. OPG expression was marked in controls but 
signifi cantly lower in aortic valve stenosis.
Areas containing focal calcifi cation exhibited signifi -
cantly less OPG-positive cells as compared to non-calcifi ed 
regions. Stimulation with RANKL lead to a signifi cant 
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rise in matrix calcifi cation, nodule formation, alkaline 
phosphatase activity, expression of the bone-type isoen-
zyme of alkaline phosphatase, and expression of osteocal-
cin in cultured human aortic valve myofi broblasts.
In conclusion RANKL and OPG are differentially 
expres sed in calcifi c aortic stenosis. In cultured human 
aortic valve myofi broblasts, RANKL promotes matrix cal-
cifi cation and induces the expression of osteoblast-associ-
ated genes, indicating a transition towards an osteogenic 
phenotype60. These results suggest that the RANKL-OPG 
pathway may regulate valvular calcifi cation in calcifi c 
aortic valve stenosis.
OPG Gene Polymorphism and Vascular 
Calcifi cation
There are several studies on the subject if and how 
OPG gene polymorphism, affect vascular calcifi cation61,62. 
All together, polymorphism among four single nucleotide 
are explored.
In the research that contains 468 men without coro-
nary artery disease, and with one, two, or three wessle 
disease diagnosed by coronarography, OPG gene polimor-
physm was performed. Although single polymorphisms 
were not associated with coronary artery disease, linkage 
of polymorphisms 950 and 1181 revealed that haplotypes 
were overrepresented in men with coronary artery disease 
with an increased risk of CAD in carriers of genotypes 950 
TC/1181 GC and 950 CC/1181 CC.
Furthermore, serum OPG levels were correlated with 
the presence of a C allele at position 950. In summary, 
linkage of genetic variations of the OPG gene at positions 
950 and 1181 may confer an increased risk of coronary 
artery disease in Caucasian men61. Certainly it would be 
interesting to extend these genetic researches on OPG 
gene polymorphism to wider population of patients, such 
as patients who develop heart failure after myocardial 
infaction, as well in patients who develop heart failure in 
severe aortic valve stenosis.
In research on Koreans, genotyping of four polymor-
phisms, A163G, G209A, T245G and T950C, in the pro-
moter region of the OPG gene was performed in 251 
healthy Korean women (mean age 51.3±6.9 years) and in 
a second study population consisting of 100 patients who 
underwent coronary angiography (mean age 57.0±11.9 
years), by allelic discrimination using the 5’ nuclease poly-
merase chain reaction assay. Cardiovascular risk factors 
and serum OPG levels were measured and aortic calcifi ca-
tion in thoracic and abdominal aorta was examined by 
simple radiological methods. That research shown preva-
lence of aortic calcifi cation increased signifi cantly as the 
subjects grew older. The frequencies of mutant alleles were 
signifi cantly higher in the subjects with aortic calcifi cation 
compared with those without aortic calcifi cation in G209A 
and T950C polymorphisms, although these signifi cances 
were lost after adjustment for age. No signifi cant relation-
ship was found between OPG gene polymorphisms and 
serum OPG levels or cardiovascular risk factors. In the 
second study group, there were no associations between 
OPG promoter genotypes and aortic calcifi cation, serum 
OPG levels, or coronary artery disease62. As we have 
shown, there,s no unique conclusion on the subject how 
OPG gene polymorphism affect vascular calcifi cation, thus 
more researches in that area are needed to clarify this 
connection.
Conclusion
Obviously there is much excitement regarding osteo-
protegerin as a linking molecule between bone and vascu-
lar system, although controversy still exists on the role of 
OPG/RANKL/RANK/TRIAL system in cardiovascular 
diseases. There is yet no joint opinion unifying dichotomy 
of OPG in animal models and human studies. It is possible 
that serum OPG levels is increased in response to the 
vascular injury and ongoing process of infl ammation 
within an atherosclerotic lesions. The high OPG levels 
probably, as shown by various studies, indicate endothe-
lial cells injury, so an increased OPG levels could be an 
indicator of a proinfl ammatory milieu in propagation of 
atherosclerosis. One hypothesis is that increased serum 
OPG levels may be a compensatory self-defensive response 
to the progression of atherosclerosis. Serum OPG levels is 
increased in the presence of one, two or three wessel dis-
ease, so it is promising as a risc stratifi cation biomarker 
amongst patients with coronary artery disease. It is dem-
onstrated that OPG provide impressive independent prog-
nostic information in patients who develop heart failure 
after acute myocardial infarction, representing a noninva-
sive tool for monitoring morbidity and mortality in these 
patients. Future studies must determine if these results 
apply solely to post-infarction heart failure or if OPG can 
provide prognostic information for a wider group of heart 
failure and acute myocardial infarction patients. Studies 
also suggest that the RANKL-OPG pathway may regulate 
valvular calcifi cation in calcifi c AS, since the RANKL and 
OPG are differentially expressed in calcifi c AS. There is 
yet to explore whether OPG gene polymorphism play any 
role in the presence and severity of cardiovascular dis-
eases, indicating that it might be genetically regulated. 
Nevertheless, the identifi cation of OPG as a novel cardio-
vascular risk marker suggests an association between 
mediators of bone homeostasis and cardiovascular dis-
eases and supports a link between bone and vascular cal-
cifi cation.
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OSTEOPROTEGERIN I VASKULARNE KALCIFIKACIJE: KLINIČKA I PROGNOSTIČKA VAŽNOST
S A Ž E T A K
Osteoprotegerin (OPG) je važan modulator koštanog metabolizma, koji ujedno manifestira svoj učinak i na krvožilni 
sustav. Pretpostavlja se da je osteopreotgerin ključni inhibitor arterijskih vaskularnih kalcifi kacija, a otpuštaju ga en-
dotelne stanice kao protektivni mehanizam za svoje preživljenje u određenim patološkim stanjima, kao u prvom redu 
šećernoj bolesti, kroničnoj renalnoj insufi cijenciji, te metaboličkim premećajima. Navedeno je pokazano u dosadašnjim 
studijama na animalnim modelima. Suprotno tome, mnoge kliničke studije posljednjih godina povezuju serumsku razinu 
osteoprotegerina sa postojanjem i težinom koronarne bolesti, ishemijskom kardijalnom dekompenzacijom, te budućih 
kardiovaskularnih događaja. Zbog navedenoga sve se više spominje njegova uloga kao potencijalnog biomarkera u ranoj 
identifi kaciji i praćenju kardiovaskularnih bolesti. Između ostaloga OPG se na osnovu kliničkih istraživanja dovodi u 
vezu i sa poznatim faktorima rizika ateroskleroze; nedvojbeno je dokazana njegova pozitivna korelacija sa dobi, te 
pušenjem. Dokazana je i pozitivna korelacija sa komplikacijama od kardiovaskularnih bolesti u pacijenata sa šećernom 
bolesti. Postoje i dokazi vezani uz povišenu razinu serumskog OPGa i hiperlipoproteinemije. Istraživanja su vršena i na 
genetskoj razini, vežući određene genske polimorfi zme pojedinih nukleotida osteoprotegerina uz pojavu vaskularnih 
kalcifi kacija. Ovaj članak naglašava multifaktorijalnu ulogu OPGa, prikazujući brojne kliničke i eksperimentalne studi-
je glede njegove uloge u vaskularnoj patologiji, predlažući novi biomarker u kardiovaskularnim bolestima, pokazujući 
nove zaključke u vezi ove zanimljive teme, koja treba daljnja istraživanja.
